

for ligation of the cystic artery and detachment of the gallbladder.

RESULTS: Reduction of the number of ports had no effect on accessibility and duration of the procedure; however, it simplified access and handling, particularly in the smaller patients. Conversion to open cholecystectomy was performed in 1 case with major deformities of the vertebral column. The duration of hospitalization varied from 1 to 4 days (mean: 2.7 days).

CONCLUSIONS: The decreased number of ports and the use of vessel sealing electrocautery make laparoscopic cholecystectomy in children easier and safe, without affecting the perioperative time.

PROCALCITONIN AS A PREDICTOR OF SEVERE APPENDICITIS IN CHILDREN

Submitted by Ioanna Velissariou

Ioanna Velissariou^a, Dimitris Kafetzis^a, Pantelis Nikolaides^b, Michael Sklavos^b, Maher Maktabi^b, George Spyridis^b, Despoina Kafetzis^a, Emmanuel Androulakakis^b

^aSecond Department of Pediatrics and ^bFirst Department of Surgery, Panagiotis and Aglaia Kyriakou Children's Hospital, Athens, Greece

INTRODUCTION: Procalcitonin is an amino acid peptide that can contribute in the diagnosis and management of severe bacterial infections because it reaches high concentrations in patients with severe bacterial infection, septicemia, or meningitis and decreases rapidly after appropriate antibiotic therapy.

OBJECTIVE: The objective of this study was to assess the diagnostic value of procalcitonin in 212 children with appendicitis and compare it with the standard diagnostic modalities, C-reactive protein, white blood cell count, and abdominal ultrasonography, in relation to the surgical and histologic findings of the appendix.

METHODS: Prolactin levels were measured in 212 children with appendicitis, and the results were compared with standard diagnostic modalities such as C-reactive protein level, white blood cell count, and abdominal ultrasonography, which are useful aids for detecting severe appendicitis and/or perforation.

RESULTS: A procalcitonin value of >0.5 ng/mL was indicative of perforation or gangrene with 73.4% sensitivity and 94.6% specificity, C-reactive protein level of >50 mg/L and white blood cell count of >10⁴/μL are useful diagnostic aids for perforation, and abdominal ultrasonography had a sensitivity of 82.8% and a specificity of 91.2%.

CONCLUSIONS: Procalcitonin seems to be a useful adjunct diagnostic tool for acute necrotizing appendicitis or perforation, and surgical exploration will probably be required in patients with procalcitonin values of >0.5 ng/mL.

Vaccination

IMMUNOGENICITY AND SAFETY OF CONCOMITANT ADMINISTRATION OF MEASLES-MUMPS-RUBELLA VACCINE AND VARICELLA VACCINE BY THE INTRAMUSCULAR OR SUBCUTANEOUS ROUTE

Submitted by Yves Gillet

Yves Gillet^a, Pirmin Habermehl^b, Anne Fiquet^c, Stephane Thomas^c, Cecile Eymin^c, Isabelle Bertrand^c, Emilio Ledesma^c

^aUrgences Pédiatriques, Hôpital Edouard Herriot, Lyon, France; ^bFacharzt Für Kinderheilkunde und Jugendmedizin, Neonatologie, Mainz-Hechtsheim, Germany, ^cSanofi Pasteur MSD, Marcy d'Etoile, France

INTRODUCTION: In Europe, recommended administration route for vaccines and physicians' preferences vary.

OBJECTIVE: The aim of this study was to compare the immunogenicity and safety profile (injection-site and systemic adverse events) of a measles-mumps-rubella vaccine (M-M-RvaxPRO) and a varicella vaccine (Varivax) when given by intramuscular or subcutaneous route.

METHODS: A total of 752 healthy children who were 12 to 18 months of age were randomly assigned to receive concomitantly at 2 separate injection sites 1 dose of both vaccines by the same route, either intramuscular or subcutaneous.

RESULTS: Six weeks after vaccination, response rates in patients who were initially seronegative were similar for all antigens (intramuscular noninferior to subcutaneous), and geometric mean titers were comparable irrespective of the administration route (Table 1). Similar numbers and types of systemic adverse events were observed in both groups, excepted for varicella/varicella-like rashes, which were less frequent in the intramuscular group. Injection-site reactions were also less frequent for both vaccines in the intramuscular group compared with the subcutaneous group (15.8% and 25.8% of patients for M-M-RvaxPRO and 20.9% and 34.3% for Varivax, respectively), but the safety pattern was comparable between groups.

TABLE 1. Response Rates and Geometric Mean Titers of the Measles-Mumps-Rubella and Varicella Vaccines When Given by Different Routes

Per-Protocol Analysis	Intramuscular			Subcutaneous		
	n	Relative Risk, %	GMTs	n	Relative Risk, %	GMTs
Measles, ≥255 mIU/mL	349	94.3	2396.4	363	96.1	2560.6
Mumps, ≥10 ELISA Ab U/mL	349	97.7	86.4	363	98.1	89.8
Rubella, ≥10 IU/mL	321	98.1	97.2	318	98.1	94.4
Varicella						
≥5 gpELISA U/mL	336	88.4	9.8	345	85.5	9.2
≥1.25 gpELISA U/mL	336	98.5	9.8	345	99.4	9.2

CONCLUSIONS: These results support both intramuscular and subcutaneous administration routes for M-M-RvaxPRO and Varivax.

**IMMUNOGENICITY AND SAFETY OF CONCOMITANT
ADMINISTRATION OF MEASLES-MUMPS-RUBELLA VACCINE AND
VARICELLA VACCINE BY THE INTRAMUSCULAR OR SUBCUTANEOUS
ROUTE**

Yves Gillet, Pirmin Habermehl, Anne Fiquet, Stephane Thomas, Cecile Eymin,
Isabelle Bertrand and Emilio Ledesma
Pediatrics 2008;121;S164

DOI: 10.1542/peds.2007-2022RRRRRRR

Updated Information & Services	including high resolution figures, can be found at: http://pediatrics.aappublications.org/content/121/Supplement_2/S164.2
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Infectious Disease http://www.aappublications.org/cgi/collection/infectious_diseases_sub Vaccine/Immunization http://www.aappublications.org/cgi/collection/vaccine_immunization_sub
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.aappublications.org/site/misc/Permissions.xhtml
Reprints	Information about ordering reprints can be found online: http://www.aappublications.org/site/misc/reprints.xhtml

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

IMMUNOGENICITY AND SAFETY OF CONCOMITANT ADMINISTRATION OF MEASLES-MUMPS-RUBELLA VACCINE AND VARICELLA VACCINE BY THE INTRAMUSCULAR OR SUBCUTANEOUS ROUTE

Yves Gillet, Pirmin Habermehl, Anne Fiquet, Stephane Thomas, Cecile Eymin,
Isabelle Bertrand and Emilio Ledesma

Pediatrics 2008;121;S164

DOI: 10.1542/peds.2007-2022RRRRRRR

The online version of this article, along with updated information and services, is
located on the World Wide Web at:

http://pediatrics.aappublications.org/content/121/Supplement_2/S164.2

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2008 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

